RESUMO
Post-exposure prophylaxis (PEP) can be a secondary measure to prevent infection by human immunodeficiency virus (HIV) when primary prevention has failed. PEP is advised for people with sporadic and exceptional risk exposure to HIV. This consensus document about occupational and non-occupational PEP recommendations aims to be a technical document for healthcare professionals. Its main objective is to facilitate the appropriate use of PEP. To this end, some recommendations have been established to assess the risk of transmission in different types of exposure, situations where PEP should be recommended, special circumstances to take into account, antiretroviral (ARV) guidelines including start and end of the treatment, early monitoring of tolerance and adherence to the treatment, subsequent monitoring of people exposed, independently of having received PEP or not, and need of psychological support. This document is intended for all professionals who work in clinical practice in the field of HIV infection.
Assuntos
Infecções por HIV/tratamento farmacológico , Hepatite B/tratamento farmacológico , Hepatite C/tratamento farmacológico , Profilaxia Pós-Exposição , Adulto , Fármacos Anti-HIV/uso terapêutico , Antivirais/uso terapêutico , Criança , Consenso , Humanos , Exposição Ocupacional/prevenção & controle , Guias de Prática Clínica como AssuntoRESUMO
The SARS-CoV-2 pandemic has caused an increase in antibiotic use in different settings. We describe the antibiotic prescribing prevalence, associated factors and trends, as well as concomitant bacterial infections in children hospitalized with COVID-19 or multisystemic inflammatory syndrome related to SARS-CoV-2 in Spain.
Assuntos
COVID-19 , Antibacterianos/uso terapêutico , COVID-19/complicações , COVID-19/epidemiologia , Criança , Humanos , Prevalência , SARS-CoV-2 , Espanha/epidemiologia , Síndrome de Resposta Inflamatória SistêmicaRESUMO
INTRODUCTION: Many human immunodeficiency virus type 1 (HIV-1)-infected children have already failed treatment with 2 or even 3 classes of antiretrovirals. Coformulation of lopinavir with low dose ritonavir exhibits a potent antiretroviral effect. However, the data in heavily pretreated children are still scarce. This study evaluated the safety and effectiveness of combination therapy including lopinavir/ritonavir in children with prior exposure to all classes of oral antiretrovirals. METHODS: This was an open label multicenter observational study, in which data were reviewed according to a standardized protocol. The study population included all HIV-1-infected children with virologic failure (HIV-1 RNA >5000 copies/mL) followed in 12 Spanish hospitals for >12 months, experienced with the 3 classes of oral antiretrovirals, in whom a lopinavir/ritonavir-containing regimen was started. RESULTS: By March 2003, 45 patients had been treated with lopinavir/ritonavir for a median of 18 months (range, 3-28). The median age at baseline was 9.7 years (range, 4.3-17.1). The median times of prior treatment were 88 months (range, 31-145) with nucleoside reverse transcription inhibitors and 42 months (range, 19-63) with protease inhibitors. Twenty-five patients were classified as Centers for Disease Control and Prevention clinical category C. Median values for absolute and percentage CD4 at baseline were 501 (range, 6-1512) and 19% (range, 0.5-49), respectively, and plasma HIV-RNA was 5.0 log10 copies/mL (range, 4.1-6.1). During follow-up, 11 (24%) children switched from liquid to solid formulation. At 48 weeks, the median values for absolute and percentage CD4 increased by 199 cells/microL and 3%, respectively, and median plasma viral load declined 1.75 log10 copies/mL. Forty-two percent of children achieved a plasma RNA of <400 copies/mL (intent to treat analysis). Baseline genotypic resistance was available in 40 children. Nonresponders had 7.0 +/- 1.6 protease inhibitor-associated mutations at baseline compared with 4.8 +/- 1.7 in children achieving virologic suppression (P = 0.06). Adverse events were described in 18 children. Three children permanently discontinued and 4 transiently withdrew lopinavir/ritonavir. At 12 months, there were mild but not significant increases in plasma cholesterol and triglycerides. CONCLUSIONS: Lopinavir/ritonavir when given as part of salvage regimen is well-tolerated, although switching to pills is frequently required. The regimen has a potent and durable antiretroviral activity in most heavily pretreated children, despite the presence of multiple mutations to all classes of oral antiretrovirals.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1/efeitos dos fármacos , Pirimidinonas/efeitos adversos , Inibidores da Transcriptase Reversa/uso terapêutico , Ritonavir/efeitos adversos , Adolescente , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Infecções por HIV/virologia , Humanos , Lopinavir , Masculino , Pirimidinonas/uso terapêutico , RNA Viral/sangue , Ritonavir/uso terapêutico , Terapia de Salvação , Resultado do TratamentoRESUMO
Treatment 2.0 is an initiative launched by UNAIDS and WHO in 2011 to catalyze the next phase of treatment scale-up for HIV. The initiative defines strategic activities in 5 key areas, drugs, diagnostics, commodity costs, service delivery and community engagement in an effort to simplify treatment, expand access and maximize program efficiency. For adults, many of these activities have already been turned into treatment policies. The recent WHO recommendation to use a universal first line regimen regardless of gender, pregnancy and TB status is a treatment simplification very much in line with Treatment 2.0. But despite that fact that Treatment 2.0 encompasses all people living with HIV, we have not seen the same evolution in policy development for children. In this paper we discuss how Treatment 2.0 principles can be adapted for the pediatric population. There are several intrinsic challenges. The need for distinct treatment regimens in children of different ages makes it hard to define a one size fits all approach. In addition, the fact that many providers are reluctant to treat children without the advice of specialists can hamper decentralization of service delivery. But at the same time, there are opportunities that can be availed now and in the future to scale up pediatric treatment along the lines of Treatment 2.0. We examine each of the five pillars of Treatment 2.0 from a pediatric perspective and present eight specific action points that would result in simplification of pediatric treatment and scale up of HIV services for children.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Assistência Integral à Saúde , Infecções por HIV , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Pediatria/normas , Adulto , Fármacos Anti-HIV/economia , Criança , Análise Custo-Benefício , Prestação Integrada de Cuidados de Saúde , Indústria Farmacêutica/economia , Feminino , Saúde Global , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/economia , Infecções por HIV/transmissão , Necessidades e Demandas de Serviços de Saúde , Humanos , Lactente , Recém-Nascido , Pediatria/educação , Gravidez , Desenvolvimento de Programas , Organização Mundial da SaúdeRESUMO
OBJECTIVE: To update antiretroviral recommendations in antiretroviral therapy (ART) in HIV-infected children and adolescents. METHODS: Theses guidelines have been formulated by a panel of members of the Plan Nacional sobre el SIDA (PNS) and the Asociacion Espanola de Pediatria (AEP) by reviewing the current available evidence of efficacy, safety, and pharmacokinetics in pediatric studies. Three levels of evidence have been defined according to the source of data: Level A: randomized and controlled studies; Level B: Cohort and case-control studies; Level C: Descriptive studies and experts' opinion. RESULTS: When to start ART should be made on an individual basis, discussed with the family, considering the risk of progression according to age, CD4 and viral load, the ART-related complications and adherence. The ART goal is to reach a maximum and durable viral suppression. This is not always possible, even with clinical and immunologic improvement. The difficulties of permanent adherence and side-effects are resulting in a more conservative trend to initiate ART, and to less toxic and simpler strategies. Currently, combinations of at least three drugs are of first choice both in acute and chronic infection. They must include 2 NA 1 1 NN or 2 NA 1 1 PI. ART is recommended in all symptomatic patients and, with few exceptions, in all infants in the first year of life. Older asymptomatic children should start ART according to CD4 count, especially CD4 percentage, that vary with age. Despite potent salvage therapies, it is common not to reach viral undetectability. Therapeutical options when ART fails are scarce due to cross-resistance. The cause of failure must be identified. Occasionally, there exists clinical and/or immunological progression, and a change of therapy with at least two new drugs still active for the patient, is warranted with the aim of increasing the CD4 count to a lower level of risk. Toxicity and adherence must be regularly monitored. Some aspects about post exposure prophylaxis and coinfection with HCV or HBV are discussed. CONCLUSIONS: A higher level of evidence with regard to ART effectiveness and toxicity in pediatrics is currently available, leading to a more conservative and individualized approach. Clinical symptoms and CD4 count are the main determinants to start and change ART.
Assuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Fármacos Anti-HIV/uso terapêutico , HIV-1 , Adolescente , Terapia Antirretroviral de Alta Atividade/métodos , Terapia Antirretroviral de Alta Atividade/normas , Criança , Ensaios Clínicos como Assunto , Humanos , EspanhaRESUMO
No disponible
Assuntos
Criança , Humanos , Tuberculose Pulmonar/tratamento farmacológico , Mycobacterium tuberculosis/patogenicidade , Antibióticos Antituberculose/farmacologia , Tuberculose Pulmonar/epidemiologia , Tuberculose Pulmonar/etiologia , Mycobacterium tuberculosis , Rifampina/farmacologia , Antibióticos Antituberculose/administração & dosagem , Resistência Microbiana a Medicamentos , Antibióticos Antituberculose/toxicidadeRESUMO
Este documento proporciona orientación sobre las intervenciones para la eliminación de la transmisión maternoinfantil del VIH y de la sífilis congénita en América Latina y el Caribe y pretende servir a los trabajadores de la salud y a los tomadores de decisiones en el campo de la salud pública para integrar la detección y tratamiento de las madres infectadas por sífilis en los tiempos y lugares en los que se detecta la infección por VIH. Debe prestarse una atención especial a las mujeres seronegativas para el VIH, a fin de brindarles servicios de prevención primaria, en especial durante el embarazo y la lactancia, ya que determinados factores biológicos y conductuales pueden aumentar el riesgo de contraer la infección durante estos períodos.
Assuntos
Humanos , Masculino , Feminino , Gravidez , Recém-Nascido , Lactente , Infecções Sexualmente Transmissíveis , Infecções por HIV , Relações Mãe-Filho , Sífilis Congênita , Transmissão Vertical de Doenças Infecciosas , Prevenção PrimáriaRESUMO
This document provides guidance on the interventions for the elimination of mother-to-child transmission of HIV and congenital syphilis in Latin America and the Caribbean, and it intends to assist the health care workers and decision-makers in charge of public health to integrate the programmes and services for the detection and treatment of syphilis and HIV in pregnant women. HIV-negative women also warrant special attention especially during pregnancy and breastfeeding, since there are certain biologic and behavioral factors that may enhance their risk of getting infected in those periods and should be provided with access to primary prevention services.